SELFDIAGNOSTICS MULTITEST COVID-19
Molecular diagnostics Multitest platform by Selfdiagnostics
So far, rapid tests have needed a confirmatory laboratory test. For the first time in history, molecular rapid tests enable diagnosis confirmation without a repeat laboratory test, giving doctors the possibility to start treatment immediately.
Selfdiagnostics Multitest COVID-19 – the rapid molecular NAAT test combines the ease of use of rapid tests and the diagnostic accuracy of laboratory PCR. It really is like having a rapid PCR in your pocket.
Selfdiagnostics Multitest COVID-19 is a good fit for the following settings
Intentionally simple and minimal component design for cost efficient mass production. Modular production line enables fast production scale-up.
Able to differentiate up to four different organism’s RNA or DNA from one sample in a single run. Duplex panel test – Selfdiagnostics STD Multitest CT/NG is in our portfolio.
Has proven multi-sample capability. Tests from swab and urine samples are ready. Expandable to detect from blood, soil and water.
ENGINEERED AND MANUFACTURED IN GERMANY
Multiplex platform and tests are developed and manufactured in Germany.
Thanks to partnerships with Fraunhofer Institute for Cell Therapy and Immunology (IZI), Dresden University of Technology, TalTech and University of Tartu Selfdiagnostics has access to top European virology labs for continued R&D and validation.
Together with Saxonian Development Bank (SAB) Selfdiagnostics fills German government order to develop and manufacture innovative testing technologies.
CE IVDR AND FDA CLEARANCE
Following first commercial availability under the CE Mark in select markets, Selfdiagnostics plans CE IVDR and FDA clearance for the Multitest COVID-19 and Multitest CT/NG in other global markets throughout 2022.